Mind Medicine (MindMed) Inc. Q3 FY2024 earnings call

Rob Barrow noted the progress in the third quarter, with plans to initiate Phase 3 studies for MM120 ODT in GAD and MDD. The development strategy leverages Phase 2b results and FDA breakthrough therapy designation, focusing on clean studies, eliminating psychotherapy, and addressing functional unblinding. Dan Karlin detailed Phase 3 study designs for GAD and MDD, including enrollment criteria and adaptive design features. Financially, the company has sufficient cash to fund operations into 2027 and anticipates R&D expenses to increase in 2025 with the Phase 3 studies.

As of September 30, 2024, Mind Medicine had cash and cash equivalents totaling $295.3 million, compared to $99.7 million as of December 31, 2023. Research and development expenses for the quarter ended September 30, 2024 were $17.2 million, an increase of $4 million from $13.2 million in the same period of 2023. General and administrative expenses were $7.6 million, a decrease of $0.8 million from $8.4 million in the same period of 2023. The net loss for the quarter was $13.7 million, a decrease of $4.2 million from $17.9 million in 2023.

Management anticipates R&D expenses to ramp up in 2025 as the second Phase 3 study in GAD and first Phase 3 study in MDD are initiated. They aim to initiate Voyage by the end of 2024, Panorama in the first half of 2025, and Emerge in the first half of 2025. Top line data from Part A of Voyage is expected in the first half of 2026, and from Part A of Panorama in the second half of 2026.

Risks include changes in market conditions, difficulties in research and development, and regulatory approval processes, as outlined in SEC and Canadian securities filings.

Q: How do you think having fewer arms in the Phase 3 program could impact central rater unblinding?

A: Rob Barrow stated that data from Phase 2 showed consistent functional unblinding across all treatment groups, and these data are informative. Functional unblinding is common in psychiatry, and studies are held to the same regulatory standard as previous drugs.

Q: Do you foresee having any particular difficulties as you look to initiate Voyage and Panorama in GAD?

A: Rob Barrow said the clinical development team is well-equipped to operationalize protocols, and they expect to continue the success seen in Phase 2, with efficient site engagement and recruitment.